TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01343719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: medium dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: medium dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: medium dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: low dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: low dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: low dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: high dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: high dose solution for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: low dose tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 661051
Description: medium dose tablet
Study: NCT02558699

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physician's personal experience
Description: physician's personal experience

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual rotor mapping
Description: Virtual rotor mapping
Study: NCT02059317

Intervention type: OTHER
Intervention: Flexion-extension in the sagittal plane
Description: The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
Study: NCT01893593

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Guideline summary and data feedback from a baseline medical record review
Study: NCT00919711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actonel®
Description: Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
Study: NCT04075604

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified Dose on Specified Days
Study: NCT02059317

Intervention type: OTHER
Intervention: Complex movement in three dimensions
Description: The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
Study: NCT04075604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Specified Dose on Specified Days
Study: NCT02059317

Intervention type: OTHER
Intervention: Complex movement in three dimensions
Description: The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.

Intervention type: OTHER
Intervention: Complex movement in three dimensions
Description: The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
Study: NCT03913728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug level blood tests
Description: All information included previously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Interview
Description: All information included previously.
Study: NCT03404869

Intervention type: DRUG
Group type: OTHER
Intervention: ORL-1M - D-mannose
Description: Oral ORL-1M
Study: NCT03289546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.
Study: NCT02447679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomine
Description: thalidomine (400mg/day) for 1 year to prevent HCC recurrence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Description: tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
Study: NCT04075604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Specified Dose on Specified Days
Study: NCT02887560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoesophageal echocardiography
Study: NCT03375814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crocin
Description: This group (osteoarthritic patients) can receive crocin with conventional therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
Study: NCT00962663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICA-105665
Description: Subjects randomized to receive ICA -105665 will receive 200 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4.
Study: NCT00743743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Longevinex brand resveratrol supplement
Description: 1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule of placebo daily for 52 weeks
Study: NCT01843452

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RADIOTHERAPY
Description: External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.~* Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).~* Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANITUMUMAB
Description: 6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MITOMYCIN
Description: 10 mg/m2 IV administered over 15 min infusion on days 1 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPECITABINE
Description: 825mg/m2 orally twice daily on study days 1 through 45.
Study: NCT03389893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
Study: NCT03728192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mangosteen extract
Description: For Mangosteen group :DNA fragmentation assay is used to identify apoptosis.1×106 cells were harvested and treated with mangosteen pericarp extract for 48 h For Camptothecin group : Cells were also treated with standard anticancer drug Camptothecin to act as a positive control.
Study: NCT01703533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
Study: NCT04075604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Specified Dose on Specified Days
Study: NCT01703533

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored solution and Water for Injection
Study: NCT01160991

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glucose clamp technique
Description: euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose clamp technique
Description: euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Glucose clamp technique
Description: euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride
Description: Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are given at 8:00 a.m.
Study: NCT04374929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StealthTrac Temporary Pacing Lead Plus Negative Pressure Wound Therapy
Description: Following fixation of the StealthTrac Lead, Negative Pressure Wound Therapy is applied over the incision site.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StealthTrac Temporary Pacing Lead Plus Anti-Inflammatory Glucocorticoid
Description: • Methylprednisolone 125 mg administered over 30 minutes beginning at least 30 minutes prior to the incision and StealthTrac Lead insertion procedure. This intravenous dose can be repeated every 8 hours on day one of the insertion from 1-3 doses depending on the patient's ability to take oral medications. It can be administered daily thereafter until the patient is able to take oral dosing. In normal circumstances, post op day 2, commence oral glucocorticoid (see below for recommended oral dosing).~Oral (PO) glucocorticoid preparations and dosing:~* Prednisone 40-60 mg orally daily based on BMI category. BMI categories: Low (\<18); Medium (18-30); High (\>30). Low and medium are assigned 40 mg daily. High BMI is assigned 60 mg daily dose. This while the StealthTrac lead remains in place.~* Methylprednisolone 16-32 mg daily based on BMI (low, medium and high) while the StealthTrac Lead remains in place.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two StealthTrac Temporary Pacing Leads (Increased Electrode Spacing)
Description: Once the first StealthTrac Lead is placed using the procedure described in the AtaCor Temporary Pacing System Instructions for Use (DOC-10085), load a second StealthTrac Lead into the same MACH I Delivery Tool, unless it was damaged during insertion of the first StealthTrac Lead, in which case a new MACH I Delivery Tool should be used.~Insert the second StealthTrac Lead through (1) a different intercostal muscle path within the same intercostal space or (2) within an adjacent intercostal space. Increased electrode spacing is achieved by pacing between the leads.

Intervention type: DEVICE
Group type: OTHER
Intervention: StealthTrac Lead Only (Control)
Description: A single StealthTrac Lead is placed with no additional treatment.
Study: NCT02239653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician communication
Study: NCT04075604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Specified Dose on Specified Days
Study: NCT01253460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: 350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
Study: NCT06257004

Intervention type: GENETIC
Intervention: Saliva collection (screening of all participants)
Description: All participants will give a salive sample (self-sampling kit) - selection of 25% extremes (UMC and AMC) participants for WGS and linkage analysis

Intervention type: GENETIC
Intervention: Saliva collection (screening of all participants)
Description: All participants will give a salive sample (self-sampling kit) - selection of 25% extremes (UMC and AMC) participants for WGS and linkage analysis

Intervention type: GENETIC
Intervention: Bloodsampling
Description: Based on the results of the WGS, a selection will be made of the 5% most extremes (UMC and AMC) participants for the iPSC-VSMC generation

Intervention type: GENETIC
Intervention: Bloodsampling
Description: Based on the results of the WGS, a selection will be made of the 5% most extremes (UMC and AMC) participants for the iPSC-VSMC generation
Study: NCT00919711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg, once every 6 months, Subcutaneous
Study: NCT03790163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
Study: NCT02306733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergometrine
Description: 100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
Study: NCT04351061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide 500 mg by mouth twice per day for 7 consecutive days.
Study: NCT04285580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Consists of 1 Bimatoprost SR administration in the study eye.

Intervention type: DRUG
Group type: OTHER
Intervention: LUMIGAN
Description: Treatment with LUMIGAN 0.01% begins on Day 1. The drop will be instilled once daily in the evening to the study eye throughout the duration of the study.
Study: NCT01639508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
Study: NCT01409759

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Perforator based interposition flap
Description: The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perforator based interposition flap
Description: The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
Study: NCT00847171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic GM-CSF-secreting breast cancer vaccine
Description: Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:~12 intradermal injections of a divided total dose of 5 x108 cells.
Study: NCT06695091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic zirconia crown
Description: All-ceramic crown
Study: NCT00577720

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: 35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks
Study: NCT06695091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic zirconia crown
Description: All-ceramic crown

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic lithium disilicate crown
Description: All-ceramic crown

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic lithium disilicate crown
Description: All-ceramic crown
Study: NCT00577720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
Study: NCT00909090

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 12 mg Lutein + Zeaxanthin
Description: 10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin, taken once daily for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Visually identical placebo
Description: Visually identical placebo, taken once daily for one year